Drug Shortage Active
DURAMORPH PF is currently in shortage. Reason: Unavailable. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
DURAMORPH PF (morphine sulfate) by Hikma is mu-opioid receptor, although it can bind to other opioid receptors at higher doses. First approved in 1984.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
DURAMORPH PF is a parenteral morphine sulfate injection approved in 1984 for moderate to severe pain management. It is a full mu-opioid receptor agonist that provides analgesia without a ceiling effect, with dosing titrated to patient response and tolerability.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team restructuring and transition focus.
mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)
Worked on DURAMORPH PF at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on DURAMORPH PF offers limited career growth due to mature lifecycle and zero linked job postings; roles focus primarily on managed decline and legacy brand stewardship. Career advancement depends on portfolio breadth beyond this single aging asset.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo